Stocksigma LogoStocksigma Logo

Concord Drugs Board to Consider Q2 FY27 Financial Results on 12th Nov'26

Concord Drugs Limited has scheduled a Board of Directors meeting on 12th Nov'26 to consider and approve the un-audited standalone and consolidated

Concord Drugs Board to Consider Q2 FY27 Financial Results on 12th Nov'26

Concord Drugs Ltd 路 Intimation 路 12 Nov 2026, 5:30 am

Concord Drugs Board to Consider Q2 FY27 Financial Results on 12th Nov'26 Concord Drugs Limited has scheduled a Board of Directors meeting on 12th Nov'26 to consider and approve the un-audited standalone and consolidated financial results for the quarter ended 30th Sep'26. In compliance with insider trading regulations, the trading window for dealing in the company's equity shares remains closed for designated persons and their immediate relatives until 48 hours following the declaration of the financial results.

Original exchange filing (PDF)

More announcements from Concord Drugs Ltd

All Concord Drugs Ltd announcements